MST for Parkinson's Disease
This study, taking place in Canada, is exploring a new treatment called Magnetic Seizure Therapy (MST) for depression in people who also have Parkinson's disease. We know that depression can be a significant challenge for people with Parkinson's, and this trial aims to see if MST is a workable and safe approach. It's a small initial study with 20 participants, focusing on whether this treatment can be introduced effectively and what its side effects might be. If this first stage goes well, it could lead to larger studies comparing MST to other treatments to find the best ways to help people with both Parkinson's and depression feel better. The goal is to improve mood without causing too many problems with memory or other brain functions.
At a glance
What is this study about?
This research study is looking into a new treatment called Magnetic Seizure Therapy, or MST for short. It's specifically for people who have both Parkinson's disease and depression. We know that depression can be a difficult symptom for many people with Parkinson's, and sometimes existing treatments don't work as well as we'd hope.
The main goal of this study is to see if MST is a good and practical treatment option for this group of people. This means finding out if patients can easily take part in the treatment, whether there are many side effects, and how well it seems to help with depression symptoms. It's a stepping stone: if this study shows MST is promising and safe, it could lead to bigger studies in the future comparing MST with other treatments to see which works best.
Researchers are particularly interested in how MST affects the heart and memory, as these are often important considerations for people with Parkinson's. The hope is to find a treatment that helps improve mood without causing new problems.
Key takeaways
- Tests a new brain stimulation treatment for depression in Parkinson's.
- Aims to see if MST is practical and safe, especially comparing heart and memory effects.
- Involves regular treatment sessions (twice a week, up to 16 times).
- Close monitoring for side effects and improvement in mood.
- This is an early-stage study to gather information for future research.
Who may be eligible?
To join this study, you would need to be at least 50 years old and have a confirmed diagnosis of Parkinson's disease, specifically at stages 1 to 4 on a common scale. You would also need to have been diagnosed with moderate to severe depression by a doctor.
It’s important that you can understand and agree to take part in the study, and that you can attend all the treatment sessions. If you are already on medication for your mood, you'd need to agree to keep those doses stable throughout the study. Your doctors will also need to confirm that this type of treatment is suitable and safe for you.
However, you wouldn't be able to join if you have other types of dementia or severe memory problems, active psychosis (like seeing or hearing things that aren't there), or certain heart conditions. You also can't have any metal objects in your head (like old clips or implants), or be on certain high doses of medications like certain sedatives or anti-seizure drugs. Being able to speak English well enough for tests is also a requirement.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 50 years old or older?
- Do you have a confirmed diagnosis of Parkinson's disease?
- Have you been diagnosed with moderate to severe depression?
- Can you attend treatment sessions twice a week?
- Do you have any metal objects inside your head (apart from in your mouth)?
- Do you have a severe heart condition?
What does participation involve?
If you decide to take part, you'll first have a detailed check-up to make sure the study is suitable for you. This includes talking to doctors and having some tests. You would give your permission (informed consent) to participate before anything else happens.
The treatment itself involves receiving Magnetic Seizure Therapy (MST) twice a week, on Tuesdays and Thursdays. Each course of treatment could last for up to 8 weeks, as you would receive a maximum of 16 treatments. During this time, your depression symptoms will be regularly checked using questionnaires.
Researchers will also closely monitor you for any side effects, especially those affecting your heart or memory. The total duration of your active involvement in the study would be approximately 18 months, happening at one specific medical centre in Canada.
Potential risks and benefits
Locations (1)
- University of British ColumbiaVerified postcodeVancouver, Canada
Common questions
What is Magnetic Seizure Therapy (MST)?
MST is a new type of treatment that uses magnetic pulses to affect brain activity, similar to how electrical pulses are used in ECT, but designed to potentially have fewer side effects.
How long will the treatment last?
You would receive treatment twice a week for up to 8 weeks, with a maximum of 16 treatment sessions.
Will I still take my usual medications?
Yes, you would typically stay on your current medications for Parkinson's and depression, but your doses would need to remain stable during the study.
Where is this study taking place?
This study is being conducted at one academic center in Canada (UBC).
What if I decide I don't want to continue?
You are free to leave the study at any time, and it won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.